Investigators evaluated the benefit of leuprorelin immediately after radical prostatectomy for prostate cancer in patients ...

LUPRON DEPOT (leuprolide acetate for extended-release injectable suspension) is a hormonal medication first approved by Health Canada in 1989 for advanced prostate cancer, and later for various ...

Secondary endpoint data from the EMBARK trial support use of enzalutamide treatments in patients with high-risk biochemically recurrent prostate cancer.

A PSA of 127 indicated a high probability of prostate cancer, leading to immediate Lupron ADT therapy and radiation treatment. Initial diagnosis and treatment left the author feeling weak and ...